Spero Therapeutics Inc
SPRO2.315USD
-0.105-4.34%
交易中 （美東）報價延遲15分鐘
130.36M總市值
虧損本益比TTM
關於 Spero Therapeutics Inc 公司
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Inc簡介
公司代碼SPRO
公司名稱Spero Therapeutics Inc
上市日期Nov 02, 2017
CEORajavelu (Esther)
員工數量32
證券類型Ordinary Share
年結日Nov 02
公司地址675 Massachusetts Ave Ste 14
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02139-3309
電話18572421600
網址https://sperotherapeutics.com/
公司代碼SPRO
上市日期Nov 02, 2017
CEORajavelu (Esther)
Spero Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
418.97K
+230558.00%
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
166.72K
+21414.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
75.00K
+20000.00%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
418.97K
+230558.00%
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-6572.00%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
166.72K
+21414.00%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
91.45K
+20000.00%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
75.00K
+20000.00%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
75.00K
+20000.00%
收入明細
單位: USD更新時間: 1月6日 週二
單位: USD更新時間: 1月6日 週二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
業務USD
名稱
營收
佔比
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
地區USD
名稱
營收
佔比
United States
5.44M
100.00%
業務
地區
業務USD
名稱
營收
佔比
Collaboration Revenue Related Party
3.05M
56.01%
Grant Revenue
2.39M
43.99%
Collaboration Revenue
0.00
0.00%
股東統計
更新時間: 2月7日 週六
更新時間: 2月7日 週六
持股股東
股東類型
持股股東
持股股東
佔比
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
其他
70.37%
持股股東
持股股東
佔比
GSK plc
16.31%
Pfizer Inc
4.19%
The Vanguard Group, Inc.
3.70%
Anson Funds Management LP.
2.85%
Renaissance Technologies LLC
2.58%
其他
70.37%
股東類型
持股股東
佔比
Corporation
20.51%
Hedge Fund
6.27%
Investment Advisor
5.88%
Individual Investor
2.87%
Investment Advisor/Hedge Fund
2.52%
Venture Capital
1.64%
Research Firm
0.20%
Bank and Trust
0.02%
其他
60.09%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
108
9.31M
16.53%
-3.08M
2025Q3
106
9.05M
16.08%
-5.89M
2025Q2
114
26.06M
46.61%
-2.84M
2025Q1
116
27.38M
49.07%
-1.56M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
GSK plc
9.19M
16.31%
--
--
Mar 27, 2025
Pfizer Inc
2.36M
4.19%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
1.99M
3.53%
+39.47K
+2.02%
Sep 30, 2025
Anson Funds Management LP.
1.60M
2.85%
-11.90K
-0.74%
Sep 30, 2025
Renaissance Technologies LLC
1.45M
2.58%
+620.60K
+74.58%
Sep 30, 2025
Alphabet, Inc.
889.98K
1.58%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
527.48K
0.94%
+16.78K
+3.29%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
433.55K
0.77%
--
--
Sep 30, 2025
Rajavelu (Esther)
188.41K
0.33%
-40.27K
-17.61%
Nov 07, 2025
Mahadevia (Ankit)
364.22K
0.65%
-6.57K
-1.77%
Aug 28, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco NASDAQ Future Gen 200 ETF
0.63%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Invesco NASDAQ Future Gen 200 ETF
佔比0.63%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
